Bronfman E.L. Rothschild L.P. raised its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 24.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,716 shares of the biopharmaceutical company’s stock after acquiring an additional 3,704 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Bristol-Myers Squibb were worth $1,043,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Tradewinds Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares during the last quarter. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in Bristol-Myers Squibb by 29.6% during the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares in the last quarter. American National Bank lifted its stake in Bristol-Myers Squibb by 11.7% during the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares in the last quarter. Finally, Heritage Trust Co purchased a new stake in Bristol-Myers Squibb during the first quarter valued at about $123,000. 69.51% of the stock is owned by institutional investors.

BMY has been the subject of a number of analyst reports. Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. SunTrust Banks, Inc. raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Barclays PLC upped their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, October 13th. Finally, BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $64.93.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.32 on Friday. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a market capitalization of $101,260.00, a P/E ratio of 20.69, a P/E/G ratio of 2.42 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the company posted $0.77 EPS. The company’s quarterly revenue was up 6.7% on a year-over-year basis. analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.54%. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Bought by Bronfman E.L. Rothschild L.P.” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://theolympiareport.com/2017/11/18/bristol-myers-squibb-company-bmy-shares-bought-by-bronfman-e-l-rothschild-l-p.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.